Ambani Orgochem H1 FY27 revenue rose 55%, profit 17-fold
Key highlights
- Ambani Orgochem reported H1 FY27 net revenue from operations of Rs 171.22 crore, up 54.87% year on year.
- H1 FY27 EBITDA was Rs 11.32 crore, compared with Rs 7.92 crore in H1 FY26.
- H1 FY27 net profit reached Rs 3.45 crore, up 1,709.33% from Rs 19.07 lakh.
- Ambani Orgochem plans to expand acrylic waterborne emulsion capacity from about 2,000 to about 4,500 tonnes per month.
powered by IRIS

Ambani Orgochem Limited reported unaudited consolidated net revenue from operations of Rs 171.22 crore for H1 FY27, ended September 30, 2026, up 54.87% year on year, while net profit reached Rs 3.45 crore, a 1,709.33% increase. The company linked the result to its stated shift toward super-specialty chemistry, capacity additions and downstream product development.
Know Ambani Orgochem inside out
Results, valuation, peers and who's buying, in one view.
What changed in Ambani Orgochem's H1 FY27 earnings?
Ambani Orgochem's reported H1 FY27 revenue increased 54.87% and net profit increased 1,709.33%. Consolidated net revenue from operations rose to Rs 171.22 crore from Rs 110.56 crore in H1 FY26, while earnings before interest, taxes, depreciation and amortisation, or EBITDA, increased to Rs 11.32 crore from Rs 7.92 crore. The unaudited results cover the half year ended September 30, 2026.
EBITDA grew more slowly than revenue, at 43.00% compared with 54.87%, based on the reported figures. Net profit, however, was Rs 3.45 crore in H1 FY27 versus Rs 19.07 lakh a year earlier, and Ambani Orgochem reported the increase as 1,709.33%. The presentation does not assign a specific financial cause to the difference between EBITDA growth and net-profit growth.
How did Ambani Orgochem's per-share earnings change?
Ambani Orgochem's earnings per share, or EPS, rose to Rs 4.02 in H1 FY27 from Rs 0.249 in H1 FY26. The company reported a 1,514.46% year-on-year increase in EPS alongside the increase in consolidated net profit to Rs 3.45 crore. EPS is the presentation's per-share measure of reported profit for the period.
The per-share improvement was larger than the 54.87% increase in revenue and followed the reported 1,709.33% rise in net profit. Management said the H1 FY27 outcome reflected business momentum and work on product capabilities, downstream opportunities, and technical and manufacturing foundations. The release provides no numerical EPS target or full-year earnings guidance.
What capacity additions is Ambani Orgochem planning?
Ambani Orgochem plans to increase acrylic waterborne emulsion capacity at Tarapur MIDC from about 2,000 tonnes per month to about 4,500 tonnes per month. This is a planned 2.25-times expansion, according to the presentation, aimed at supporting waterproofing, pressure-sensitive adhesives, carpet binders and road-infrastructure applications. The company describes the project as an ongoing expansion rather than a completed capacity increase.
The acrylic waterborne emulsions division targets paints, coatings, adhesives, carpets, construction, textiles and paper. Management's stated operating focus is to scale capacity, advance formulations and develop application-led opportunities. No capital-expenditure amount, commissioning date, utilisation level or expected revenue contribution was disclosed for the move from about 2,000 to about 4,500 tonnes per month.
Got a follow-up? Ask IRIS
How is Ambani Orgochem expanding its salicylate portfolio?
Ambani Orgochem plans to expand salicylic acid and derivative capacity from about 40 tonnes per month to about 200 tonnes per month, a five-times increase. The company said it is using its in-house salicylic acid manufacturing capability as the base for value-added derivatives with potential uses in cosmetics, fragrance, personal care, pharmaceuticals and specialty chemicals.
Its disclosed development pipeline contains more than 12 salicylate molecules, with selected molecules progressing toward plant trials. The named products include octyl, 2-ethylhexyl, cyclohexyl, amyl, benzyl, isopropyl, hexyl, heptyl, homo-methyl, sakura, iso-amyl and iso-butyl salicylates. Ambani Orgochem characterises this as a plan to move downstream and broaden its molecule portfolio, not as a disclosure of commercial sales from development-stage products.
What is Ambani Orgochem doing in peroxide derivatives and metal octoates?
Ambani Orgochem has more than 20 existing peroxide products and is developing five additional peroxide molecules. It also said di-tert-amyl peroxide, or DTA, was developed through in-house research and development. The peroxide platform serves polymer processing, composites, rubber, elastomers and other industrial applications through specialised manufacturing infrastructure.
The company is developing two critical peroxide raw materials in-house, with pilot trials nearing completion. Management said these inputs could potentially support about six additional peroxide molecules, subject to validation and commercial assessment. In metal octoates, Ambani Orgochem supplies cobalt, zirconium and calcium octoates for coatings, composites, printing and woodcare, including paint driers, fibre-reinforced plastic accelerators, inks and wood preservation.
Conclusion
The H1 FY27 figures show revenue growing faster than EBITDA, with net revenue up 54.87% to Rs 171.22 crore and EBITDA up 43.00% to Rs 11.32 crore. Net profit rose from Rs 19.07 lakh in H1 FY26 to Rs 3.45 crore, while EPS increased from Rs 0.249 to Rs 4.02, against the company's strategy of building specialised product and application capabilities.
The next developments to watch are execution of the Tarapur acrylic-emulsion expansion toward about 4,500 tonnes per month, selected salicylate plant trials and completion of pilot trials for two peroxide inputs. Management said those inputs could potentially support about six additional peroxide molecules, subject to validation and commercial assessment, while the release cautions that forward-looking statements may differ from actual outcomes.


